The Enthesopathy Treatment Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

New York City, NY -- (SBWire) -- 03/17/2017 --The Enthesopathy Treatment Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Enthesopathy Treatment Market: Dynamics

The demand for enthesopathy treatment is expected to upsurge owing to the increasing number of sports injury, rising number of population going for workouts for good fitness score and the growing number of pathological research and increasing number of product pipeline by industry players. In around 4% of the population enthesopathy precede arthritis and is accompanied with morning heel pain and foot stiffness. Moreover, industry players are involved in expanding the product portfolio related to rheumatology. Janssen Biotech, Inc. presented more than 35 articles related to rheumatology portfolio at the American College of Rheumatology. The data included efficacy and safety data from Phase 3 studies of Stelara, Simponi Aria and Simponi.

Enthesopathy Treatment Market: Market Players

Some of the enthesopathy treatment market contributors include Abbott Laboratories, Accuray Incorporated, Boston Scientific Corporation, C.R. Bard, Inc., Eli Lilly and Company, Janssen Biotech, Inc., Pfizer, Inc., Siemens AG, Varian Medical Systems, Inc., and Ultragenyx Pharmaceutical, Inc.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14707

Enthesopathy Treatment Market: Region-wise Outlook

North America dominated the enthesopathy market owing to the industry participant research undertakings and government efforts towards arthritis treatment awareness. Ultragenyx Pharmaceutical, Inc. initiated a Phase 3 study for the treatment of pediatric patients with X-linked hypophosphatemia (XLH). XLH is a condition wherein there is inadequate mineralization of bones which leads to abnormalities such as enthesopathy, osteoarthritis and many more. Moreover, in the U.S. arthritis is not limited to older person but also prevalent in children. On the Juvenile Arthritis Awareness month there were 250 children diagnosed with juvenile arthritis. Asia Pacific is expected to be fastest growing region owing to the high incidence rate of arthritis thus posing a high enthesopathy treatment opportunity for international as well as domestic players. In India, obesity precede arthritis and hence the incidence rate of arthritis is high.

To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/14707